Cullinan Therapeutics (CGEM) Invested Capital: 2020-2023
Historic Invested Capital for Cullinan Therapeutics (CGEM) over the last 3 years, with Sep 2023 value amounting to $468.8 million.
- Cullinan Therapeutics' Invested Capital fell 20.01% to $468.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $468.8 million, marking a year-over-year decrease of 20.01%. This contributed to the annual value of $535.0 million for FY2022, which is 25.78% up from last year.
- According to the latest figures from Q3 2023, Cullinan Therapeutics' Invested Capital is $468.8 million, which was down 6.16% from $499.6 million recorded in Q2 2023.
- Over the past 5 years, Cullinan Therapeutics' Invested Capital peaked at $604.6 million during Q2 2022, and registered a low of $200.3 million during Q4 2020.
- Its 3-year average for Invested Capital is $490.8 million, with a median of $469.7 million in 2021.
- In the last 5 years, Cullinan Therapeutics' Invested Capital surged by 112.35% in 2021 and then fell by 20.01% in 2023.
- Quarterly analysis of 4 years shows Cullinan Therapeutics' Invested Capital stood at $200.3 million in 2020, then surged by 112.35% to $425.4 million in 2021, then grew by 25.78% to $535.0 million in 2022, then decreased by 20.01% to $468.8 million in 2023.
- Its last three reported values are $468.8 million in Q3 2023, $499.6 million for Q2 2023, and $485.6 million during Q1 2023.